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Abstract
Chronic pancreatitis is a fibroinflammatory syndrome of the pancreas that 
results in exocrine and endocrine pancreatic insufficiency and chronic pain. It can 
be seen in all age groups depending on the etiologic factors. It is believed that alco-
hol is one of the major etiologic factors of chronic pancreatitis, but it is now recog-
nized that alcohol is responsible for 50% of the cases. Mutations in many genes such 
as PRSS1, SPINK1, CTRC, CFTR are identified as causative or predisposing factors 
for CP. Early diagnosis and staging of CP are still a challenge in clinic. Although the 
chief complaint of patients with CP is abdominal pain, CP can cause many disorders 
such as diabetes or metabolic bone diseases. The treatment of CP mainly depends 
on the severity of the disease and morphology of the pancreas. Medical therapy, 
endoscopy and surgery are all used for the treatment of CP and its complications.
Keywords: pancreas, chronic pancreatitis, endoscopy, gastroenterology, 
endosonography
1. Introduction
Chronic pancreatitis (CP) is characterized by fibroinflammatory inflammation 
of pancreatic tissue that causes progressive and irreversible destruction of the exo-
crine pancreas and loss of islets of Langerhans. The cause of the chronic pancreatitis 
is often multifactorial, involving chronic alcohol usage, recurrent acute pancreatitis 
attacks, structural or genetic anomalies.
2. Epidemiology
CP can be seen in all age groups depending on the etiologic factors. Although 
true prevalence is approximately < 50 per 100,000 adults, peaking in patients aged 
46–55 years, the determination of its prevalence is difficult because of local stan-
dards and reporting bias. The incidence is predicted to be 4 to 5 new diagnoses per 
100,000 yearly [1]. Data from Italian, Spanish, Chinese and Japanese surveys have 
the similar results as mentioned above [2].
CP is a slightly male predominant disease due to more alcohol and tobacco usage. 
Recently, several studies aimed to explain male sex predominance with the changes 




Hospital admission for acute and chronic pancreatitis are increasing in the 
United States. Pancreatitis (acute and chronic) was among the three most com-
mon benign gastrointestinal diagnoses and accounted for a 12% increase in 
emergency room visits since 2006 according to US registry-based analysis that was 
published in 2019 [5]. Considering the stable or decreasing tobacco and alcohol 
use in most western countries and the probable unchanging prevalence of genetic 
risk factors, greater sensitivity of diagnostic testing can be the cause of increased 
hospital admissions. Approximately 3–35% of patients with a first episode of acute 
pancreatitis will progress to chronic pancreatitis over 3–8 years [6, 7]. Oppositely, 
only about 50% of patients with chronic pancreatitis had previously documented 
episodes of acute pancreatitis [8].
Black patients suffer more severe pain and disability and have more advanced 
morphological changes on the imaging techniques compared with white patients 
[9]. These results can be explained by more frequent usage of alcohol and 
tobacco in those patients. CP, like in many countries, is a male predominance 
disease in Turkey. The median age of the disease is 46 for male patients and 
50 for female patients. The main etiological factor for the disease is alcohol 
abuse [10].
3. Etiology
It is believed that alcohol is one of the major etiologic factors of chronic pancre-
atitis, but it is now recognized that alcohol is responsible for 50% of the cases [3]. 
Therefore, stigmatization of patients with chronic pancreatitis as having an alcohol 
use disorder is often inaccurate and unfitting. It has been estimated that patients 
must consume 4–5 alcoholic drinks per day consistently for over 5 years to be at risk 
[11]. Alcohol exposure has several unwanted effects to the pancreas tissue. Despite 
common knowledge, it makes pancreas more susceptible to injury rather than 
directly causing chronic pancreatitis.
Usage of tobacco products is another risk factor for chronic pancreatitis. In the 
past, it was assumed cigarette smoking caused chronic pancreatitis due to concur-
rent alcohol consumption, but studies demonstrated a link between an indepen-
dent and dose-dependent response of tobacco usage and chronic pancreatitis [12]. 
Also, cigarette smoking is a strong risk factor for recurrent acute pancreatitis 
which can eventually progress to chronic pancreatitis. Smoking is related to the 
induction of interleukin-22 secondary to aryl hydrocarbons, which promote 
pancreatic fibrosis [13].
Recurrent episodes of acute pancreatitis can lead to pancreatic fibrosis, 
gland atrophy, loss of islet of Langerhans which eventually progress into chronic 
pancreatitis.
Hereditary pancreatitis is another etiologic factor for developing chronic pancre-
atitis. It is observed as an autosomal dominant mutation of the cationic trypsinogen 
gene (PRSS1). Hereditary pancreatitis is an autosomal dominant disease with high 
penetrance up to 80% but some patients can also develop the PRSS1 gene mutation 
de novo.
Another mutation can also be the cause of chronic pancreatitis. Including 
genes that encode serine peptidase inhibitor Kazal type 1 (SPINK1), chymotryp-
sin C (CTRC), calcium-sensing receptor (CASR), claudin (CLDN2) and cystic 
fibrosis transmembrane conductance regulator (CFTR). Due to CFTR gene muta-
tion cystic fibrosis is another etiologic risk factor for chronic pancreatitis. Also, 
Carboxypeptidase A1 (CPA1) and carboxyl ester lipase (CEL) gene mutations are 
thought to be increasing risk factors for chronic pancreatitis.
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There are two unique subtypes of chronic pancreatitis. The first subtype is 
referred to as tropical pancreatitis (previously fibro calculous pancreatitis) which is 
mostly seen in Southeast Asia, especially in India. Previously, the cause of tropical 
pancreatitis was believed to be cassava root ingestion. However, this hypothesis has 
not been supported. Half of the patients who suffer from tropical pancreatitis show 
SPINK1 gene mutation, but the pathogenesis of the tropical pancreatitis remains 
unexplained [14].
The other subtype of chronic pancreatitis is autoimmune pancreatitis (AIP) 
which is subclassified as type 1 AIP (lymphoplasmacytic sclerosing pancreatitis) 
and type 2 AIP (idiopathic duct-centric pancreatitis). AIP, especially lymphoplas-
macytic sclerosing pancreatitis is associated with IgG4-secreting plasma cells in 
the pancreas. Type 1 AIP has also extra pancreatic manifestations like sclerosing 
cholangitis and retroperitoneal fibrosis. Patients eventually develop pancreatic 
calcifications and pancreatic insufficiencies that are indistinguishable from chronic 
pancreatitis.
Less commonly, hypercalcemia (generally due to parathyroid adenoma), hyper-
triglyceridemia, autoimmune disorders (eg, celiac disease, inflammatory bowel 
diseases) can cause chronic pancreatitis.
Approximately 40% of the chronic pancreatitis patients’ etiology is 
unknown [15].
4. Pathogenesis
The exact pathogenesis underlying the chronic pancreatitis is not totally defined. 
The disease most commonly occurs due to environmental factors such as alcohol 
and smoking or in patients with genetic abnormalities. However, idiopathic CP 
affects almost 50% of people with this condition [15]. Some hypotheses for the 
pathophysiology are proposed to explain the etiologic factors. These can give us 
ideas about the mechanism about the development of the chronic pancreatitis.
4.1 Toxic – metabolic
Excessive alcohol consumption is responsible for 50% of the chronic pancreatic 
cases [16]. Alcohol is also the best-known etiologic factor in the world, so that 
patients can be stigmatized with alcoholism and this leads to lower quality of life. It 
is shown that alcohol is toxic to acinar cells, pancreatic ducts and its microcircula-
tion [17, 18]. It was supposed that alcohol causes to spasm of the sphincter of Oddi, 
and it affects the character of pancreatic fluid to favor the formation of protein 
plugs and stones, which eventually lead to chronic pancreatitis [19]. However, these 
two theories failed to fully explain the pathogenesis of the alcoholic pancreatitis, 
scientists focused on the acinar the effect of the alcohol on the acinar cells, which 
are full of thousands digestive enzyme molecules. Normally, the enzymes are pro-
duced as inactive precursors, packed into zymogen granules, and segregated from 
mainly lysosomal enzymes in order to avoid premature activation [19]. Alcohol 
leads to destabilization of lysosomes and zymogen granules via by oxidant stress 
produced by cholesteryl esters (CEs), which accumulate in the pancreas during 
ethanol consumption; and fatty acid ethyl esters (FAEEs), which are nonoxidative 
metabolites of alcohol. The enzyme synthesis is increased, but the secretion is also 
impaired. Therefore, it predisposes the gland to autodigestive injury. The cytokines 
released during prolonged injury and the ethanol itself via its metabolite acetalde-
hyde causes activation of the PSC (specific, highly plastic type of myofibroblast) 
leading to excess deposition of extra cellular matrix and active tissue remodeling 
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and resulting in fibrosis and replacement of functional tissue [20–23]. Smoking is 
also common in patients with CP. It is convincingly demonstrated that smoking has 
an independent from alcohol, dose-dependent effect for developing CP. In addition, 
it is a facilitating factor for progressing of acute pancreatitis to CP. Furthermore, 
smoking promotes the fibrosis by inducing the IL-2 [13]. A potent toxic component 
of nicotine metabolite causes trypsinogen activation and cellular damage leading to 
pancreatitis [24].
4.2 Inappropriate protease activation
Pancreatic acinar cells secrete proteases as precursor enzymes, which are then 
activated by the serine protease in the duodenum [25]. Trypsin, the precursor of the 
major protease trypsinogen, starts the activation cascade of many other proteases, 
and itself in the duodenum (autoactivation). The natural inhibitors of the intrapan-
creatic activation are the SPINK1, trypsinogen degradation by CTRC and cathepsin 
L. Most genetic mutations associated with CP are trypsin dependent. Premature 
intrapancreatic activation or inappropriate inhibition of the trypsinogen can lead to 
pathologic event resulting in CP [26].
4.2.1 PRSS1 and PRSS2
Hereditary pancreatitis (HP) is a specific subtype of CP. The mutations in 
the human cationic trypsinogen (PRSS1) can cause the premature activation of 
the trypsinogen in various ways. 90% percent of the HP patients diagnosed with 
PRSS1 mutation carry one of the 3 mutations: p.N29I, p.R122C, or p.R122H in the 
heterozygous state. The p.N29I variant causes an increase in N-terminal process-
ing, decreased CTRC -dependent degradation, and an increased propensity for 
autoactivation of the trypsin. The p.R122C and p.R122H mutations mainly prevent 
CTRC-mediated trypsinogen degradation [27–29].
There is no pathologic variants of human anionic trypsinogen (PRSS2) found in 
patients with CP. Even Genome wide association studies (GWASs) have identified 
a protective PRSS2 locus that slightly decreases CP risk, with a more pronounced 
effect in alcoholic [30].
4.2.2 SPINK1
The gene that encode serine peptidase inhibitor Kazal type 1 (SPINK1) is found 
to be associated with CP and commonly observed (40–50%) in tropical pancreati-
tis, which was referred as fibrocalculous pancreatitis [14]. The variant p.N34S in 
SPINK1 gene is ten times often in patient with CP compared to normal population 
[31]. However, the pathophysiologic mechanism is not yet known clearly although it 
is accepted as a major risk factor for CP.
4.2.3 CTRC
CTRC is a digestive protease synthesized and secreted by the pancreatic acinar 
cells as an inactive proenzyme (zymogen), which becomes activated in the duode-
num. Physiologic functions include degradation of trypsin and trypsinogen, as an 
important defensive mechanism in chronic pancreatitis [32]. Besides, CTRC is not 
only a digestive enzyme but also plays a role in regulating the activity of other diges-
tive enzymes such as stimulating autoactivation of human cationic trypsinogen 
[28]. Furthermore, CTRC is an essential co-activator of pro carboxypeptidase A1 
(pro CPA1) and pro carboxypeptidase A2 (pro CPA2) [33].
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Mutations in the CTRC gene have been shown to increase the risk of CP and they 
are 30% prevalent among patients with CP. The three main pathways explaining the 
increased risk of CP involve (i) impaired trypsinogen and/or trypsin degradation; 
(ii) impaired activation of A-type carboxypeptidases, and (iii) induction of ER 
stress due to defective secretion [32].
4.2.4 CTRB
CTRB1 and CTRB2 genes encode a member of the serine protease family of 
enzymes. The study by Rosendahl et al. reported the identification of CTRB1-
CTRB2 (chymotrypsin B1 and chymotrypsin B2) as a new chronic pancreatitis (CP) 
risk locus by means of GWAS. The inversion is found to decrease the CP risk by 
increasing trypsinogen degradation [34].
4.2.5 CELA3B
Recently, researchers found a new protease mutation linked to hereditary 
pancreatitis. The missense mutation in the gene encoding pancreas-specific prote-
ase elastase 3B (CELA3B), which upon secretion and activation by trypsin leads to 
uncontrolled proteolysis and recurrent pancreatitis [35].
4.3 Ductal dysfunction
After joining the common bile duct, the main pancreatic duct, after which both 
ducts perforate the medial side of the second portion of the duodenum. Therefore, 
any obstruction, compression or inflammation of the pancreatic tissue will increase 
the pressure within the pancreatic ducts leading to ductal dilation, stenosis and to 
atrophy of the acinar cells and replacement by fibrous tissue [36]. Long standing 
ductal obstructions by pseudocyst, calculi or pancreatic division can be a reason 
for recurrent pancreatitis attacks, which lead to eventually fibrosis and pancreatic 
insufficiency. Ductal obstruction can be also caused by concretions which increase 
the viscosity of the secretions and thereby promoting protein plugging [37].
A distinct form is the pancreatitis resulting due to a mutation in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. CFTR is a chlo-
ride–bicarbonate channel expressed in the apical plasma membrane of secretory 
epithelia in many organs such as pancreas. The channel controls transepithelial 
fluid secretion and hence hydration of the epithelial luminal surfaces. It also con-
trols the pH of the secretions, which is important for the optimal digestion [38]. 
Genetic variations in CFTR that affect membrane levels or channel activity led to 
various pancreatic phenotypes including chronic pancreatitis. Aberrant expression 
of CFTR causes to diminished fluid and HCO3− secretion leading to decreased 
intraluminal pH, decreased washout of the digestive enzymes, and more viscous 
protein rich ductal fluid. These changes promote the formation of intraluminal 
protein plugs [39, 40].
4.4 Oxidative distress
Moreover, a hypothesis is proposed which implies that mutation-induced mis-
folding, secretory blockage, and consequent endoplasmic reticulum (ER) stress can 
lead to acinar cell damage and pancreatitis [41]. Some of associated genes are CPA1 
and CEL. Recent studies have also reported CLDN2, and MORC Family CW-Type 
Zinc Finger 4 (MORC4) gene are associated with CP, but the mechanism has not 
elicited, yet [4, 14].
Pancreatitis
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Pathogenic CPA1 variants are detected both late but especially early onset CP 
due to proenzyme mis-folding, resulting in a secretion defect and intracellular 
retention [42, 43]. A deletion mutation in CEL is founded to cause an increasement 
in ER stress, through activation of the unfolded protein response and causing cell 
death by apoptosis [44].
The pancreas consists of three critical cell lineages: acinar, ductal and endo-
crine46. Adjacent to the acinar cells around small pancreatic ducts and blood vessels 
are pancreatic stellate cells, that compromise around 4–7% of all parenchymal cells 
[45, 46]. The hypotheses mentioned above lead to cellular injury, which turns into 
chronic inflammation and then eventually fibrosis.
As explained before, the secretory parenchyma but mainly the acinar cells are 
destroyed by processes such as toxification, inflammation, duct obstruction or 
oxidative stress. Increasing evidence indicates that pancreatic stellate cells (PSC) are 
the major mediators of fibrosis, resulting in the formation of extracellular matrix 
(ECM) in the organ. Fibrosis causes acinar cells and duct cells to injure and disap-
peared. This process ultimately leads to progressive loss of the lobular morphology 
and structure of the pancreas resulting in functional impairment of both exocrine 
and endocrine functions, eventually leading to clinical symptoms such as pain, 
malnutrition, or diabetes [47, 48]. Furthermore, the pancreatic stellate cells activate 
into myofibroblast-like phenotypes, proliferate, and secrete collagen I and III and 
fibronectin [49, 50]. Hence, the initial of the pancreas, leads to cell necrosis and/or 
apoptosis and consequently release of cytokines/growth factors (e.g., tumor growth 
factor b1, interleukin-8, platelet-derived growth factor and CC-chemokines), either 
from immigrating inflammatory cells, especially macrophages, and/or nearby 
preexistent epithelial or mesenchymal cells [51–54]. Thereafter damaged cells are 
phagocytosed by macrophages, causing release of cytokines, which in turn causes 
activation and proliferation of PCS [55]. So, a vicious circle of the irreversible event 
has started. These metalloproteinases are in return regulated by cytokine tumor 
growth factor (TGF)-β1s, which through autocrine inhibition enhances pancreatic 
fibrogenesis by reducing collagen degradation [50].
5. Diagnosis
The diagnosis of the chronic pancreatitis is still challenging especially in the 
early stages of the disease. Clinician must be suspected chronic pancreatitis in 
a patient with chronic abdominal pain (especially in upper quadrants), weight 
loss, steatorrhea, and endocrine pancreatic insufficiency. All patients with 
suspected chronic pancreatitis should have a dedicated pancreatic protocol to 
rule out pancreas carcinoma. Clinician should remember that any patient with 
chronic abdominal pain may also be had suffered from chronic abdominal pain 
syndrome, history of ERCP-related pancreatitis or any ductal changes. In most 
cases follow-up with serial imaging and physiological tests are recommended 
[56]. Once the diagnosis is confirmed, physician should characterize the etiology 
of chronic pancreatitis. TIGAR-O classification and modified MANNHEIM clas-
sification should be evaluated. TIGAR-O classification is a mnemonic for toxic 
metabolic, idiopathic, genetic mutations, autoimmune, recurrent, and severe 
acute pancreatitis associated chronic pancreatitis and obstructive etiologies [46]. 
Modified MANNHEIM classification is a mnemonic for multiple risk factors, 
alcohol consumption, nicotine consumption, nutritional factors (hyperlipidemia, 
hypertriglyceridemia), hereditary factors, efferent duct factors, immunologic 
factors, miscellaneous factors (hypercalcemia, hyperparathyroidism, chronic 
renal failure, toxins) [45].
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Contrast-enhanced CT should be the initial diagnostic tool. CT scans have an 
overall sensitivity of 75% for chronic pancreatitis. Enlargement of the main duct 
(2–4 mm), glandular enlargement, heterogenous parenchyma, small (<10 mm) 
or lager (>10 mm) cavities, irregular ductal borders, irregular head/body contour 
and increased echogenicity of main duct wall are the probable pathologies that are 
seen in CT scan. After seeing these pathologies physician should suspect chronic 
pancreatitis and follow-up the patient. The other imaging technique for chronic 
pancreatitis is MRI and MRCP. Current MRI and MRCP technologies can provide 
high-quality images both parenchyma and ductal system [56]. T1 sequence in MRI 
is helpful for evaluating parenchymal changes in chronic pancreatitis. MRCP is used 
for evaluating ductal changes in chronic pancreatitis. Intravenous secretin adminis-
tration during MRCP imaging stimulates pancreatic fluid secretion and can improve 
the visualization of ductal tree [57]. The other imaging technique for evaluating 
chronic pancreatitis is ultrasonography and endoscopic ultrasonography (EUS). 
EUS finding can be classified as two subgroups which are parenchymal features 
and ductal features [58]. EUS is one of the most promising imaging techniques for 
diagnosis and evaluating chronic pancreatitis. However, the EUS imaging needs 
experienced clinician. EUS is now considered to be the most sensitive CP diagnostic 
investigation, especially in the early stages of the disease [59, 60].
Blood amylase and lipase levels can help the physician to diagnose acute pancre-
atitis however, in chronic pancreatitis these levels often normal. The diagnosis of 
the chronic pancreatitis with blood tests are challenging. There can be some clues 
like hypertriglyceridemia, hypercalcemia, hyperparathyroidism and hyperlipid-
emia. On the other hand, fecal elastase levels are often decreased in chronic pan-
creatitis. Also, diagnosis of type 3c diabetes (defined as pancreatic islet dysfunction 
and islet loss due to diseases of endocrine pancreas) is helpful for diagnosing the 
disease. Increased levels of hemoglobin A1c (HbA1c), absence of insulin resistance, 
loss of incretin secretion and low levels of fat-soluble vitamin concentrations can 
support the diagnosis of the chronic pancreatitis. The secretin stimulation test can 
be used with MRCP and for research. Secretin stimulation test is a complex proce-
dure. Firstly, the physician takes a sample from duodenal fluid as a baseline enzyme 
value then performs intravenous secretin administration after that the second 
sampling from duodenal fluid is done. Fecal elastase levels and secretin stimulation 
test results show the damage of exocrine pancreas.
6. Clinical presentation
The most common symptom of chronic pancreatitis is abdominal pain which is 
present more than 80% of patients. The pain is commonly described as a dull pain 
in the epigastrium radiating to the back that worsens after meals. The character, 
pattern and intensity of pain can vary among patients and does not correlate with 
the extent of pathological/morphologic changes [61]. Patients with alcohol related 
CP are more likely to experience pain, whereas late-onset CP is stated to be less 
painful [62]. Nausea, vomiting or both may accompany pain during exacerbations 
of pain attacks or during episodes of acute pancreatitis. Approximately 70% of 
adult patients with CP experience at least 1 episode of acute pancreatitis and 50% 
have recurrent pancreatitis during the clinical course of the disease [63].
Several anatomical complications can occur in CP due to local inflammation 
or glandular fibrosis symptoms. The formation of pancreatic pseudocysts, which 
can occur in 10–40% of patients during their lifetime, is one of the most frequent 
anatomic complications. Pseudocysts can cause gastroduodenal outlet obstruction 
and/or biliary obstruction, depending on their anatomic location and size [64].
Pancreatitis
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Other anatomical complications are pancreatic stones, pancreatic strictures, 
biliary strictures and thrombosis of splanchnic vasculature.
One of the complications of CP is exocrine pancreatic insufficiency (EPI). 
EPI is a condition characterized by insufficient production and/or secretion of 
pancreatic enzymes for the digestion of nutrients. The predominant symptoms 
of EPI are related to fat malabsorption. Mild EPI can cause abdominal bloating 
and discomfort, while severe EPI can cause overt steatorrhea, weight loss and 
fat-soluble vitamin deficiencies. Generally, EPI does not develop for more than 
a decade after disease onset, due to the exceptional reserve of the exocrine pan-
creas and the redundant pathways for digestion of proteins and carbohydrates. 
Although prevalence of EPI at diagnosis of CP is 10–13%. EPI affects more than 
70% of patients with CP throughout their lifespan and is especially frequent in 
those with proximal obstruction of the pancreatic duct or a history of pancreatic 
resection [64, 65].
Another complication of CP is metabolic bone disorder which has also been 
referred to as CP-associated osteopathy. A meta-analysis estimated that the pooled 
prevalence of osteoporosis was 23.4% and of osteopenia, 39.8% [66]. Additionally, 
patients with CP have a higher risk of low trauma fractures (vertebrae, hip, and 
wrist) and the risk of fractures in patients with CP was similar to other gastrointes-
tinal diseases, such as cirrhosis, celiac disease and history of gastrectomy [67].
Diabetes mellitus (DM) is a frequent complication of CP. Prevalence of endo-
crine insufficiency at diagnosis of CP is 10–33% [4, 8]. A recent systematic review 
identified a 15% prevalence of new onset diabetes within 36 months and a 33% 
prevalence within 60 months of CP diagnosis [68]. DM usually occurs several years 
after the onset of the disease and can eventually affect up to 80% of patients over 
their lifespan [69]. Due to the high prevalence of CP-DM, annual screening for DM 
is recommended [70, 71]. In a recent study of participants with CP, DM was more 
likely to occur in participants who were older, obese, male, black race, or had a 
family history of DM and factors independently associated with DM included both 
obesity and the presence of exocrine pancreatic insufficiency [72]. A prolonged 
period of CP, the absence of pain, cigarette smoking, and an increase in visceral 
adipose tissue have all been linked to CP-DM [73, 74].
7. Medical treatment of the pain
Chronic Pancreatitis related pain is typically among the most severe pain of all 
chronic diseases and has a major impact on quality of life and disability [16, 17]. 
That is why pain control plays a key role in the treatment of CP. Combinations of 
medical, endoscopic, and surgical approaches may be used to relieve abdominal 
pain in patients with CP [75, 76].
All patients having pain should be offered medical management. Patients with 
inflammatory mass, pancreatic duct obstruction due to stricture and/or main duct 
stones or peripancreatic complications (e.g. pseudocyst) may require additional 
interventions. Even in patients who tend to be suitable for endoscopic or surgical 
therapy, initial medical management of pain is advised to provide relief, greater 
understanding of the mechanism of pain, response to treatment, and if there is any 
significant sensitization [77].
The World Health Organization analgesic ladder for cancer pain is widely used 
by physicians to treat CP pain as there are no recommendations for the choice, 
usage and dosage of analgesics [78]. This stepwise approach recommends acet-
aminophen and nonsteroidal anti-inflammatory drugs (e.g., diclofenac, ibuprofen, 
and naproxen) as initial choice. When patient has constant and/or severe pain that 
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cannot be controlled with non-narcotic analgesics, narcotic medications can be 
used. The first option of narcotics should be a weaker, mixed agonist–antagonist 
or partial agonist (e.g., tramadol) prior to the use of stronger narcotics (e.g., 
morphine, hydrocodone and hydromorphone). If opioids are needed, they should 
be administered orally in a long-acting form -lancet). Physicians must be aware of 
their side effects (e.g., constipation, nausea, sedation, increased risk of falls, and 
risk of dependence and substance misuse) and capable of managing them. That is 
why, patients that are likely to undergo long-term narcotic analgesia for pancreatic 
pain are most effectively assessed and treated at a pain clinic [77].
Because of these adverse effects of opioids, co-analgesics should also be tried, 
and interventional therapy (such as surgery) should be considered before starting 
opioids. Co-analgesics such as antidepressants and anticonvulsants (gabapentin, 
pregabalin) have been shown to be beneficial in the treatment of chronic visceral 
and neuropathic pain in chronic pancreatitis and can help to minimize the need for 
opioids [62, 79]. Pregabalin is shown to have better efficacy in decreasing daily pain 
scores than placebo, however central nervous symptoms were seen in significant 
number of participants on pregabalin, potentially limiting its clinical usefulness 
[80]. Alternative analgesics such as esketamine are currently being investigated for 
this indication [61].
Antioxidant supplementation in may be beneficial especially for those patients 
with nonalcoholic-derived CP but additional trials are needed [81–83]. A random-
ized control study showed that pain relief significantly higher in the antioxidant 
group than in the placebo group [84].
8. Endoscopic treatment of the CP
Unfortunately, 30 and 60% of all patients ultimately require intervention. 
Endoscopic interventions have an important place for both in the diagnosing/stag-
ing of the disease and in the management of the CP complications [85].
8.1 Treatment of the pain
Although all therapeutic approaches for pancreatic pain is not very effective, 
endoscopic therapy is still one of the choices in patients whose pain is refractory to 
non-interventional therapy and who has remarkable anatomic alterations in their 
pancreas and/or in the surrounding tissue. There is no evidence for the use of the 
endoscopy in the mild disease or in painless CP [86–88]. Endoscopic therapy could 
be beneficial in patients with a symptomatic pancreatic duct obstruction in the 
pancreatic head or neck, together with an upstream duct dilatation, Plastic stents 
and fully covered self-expandable metal or biodegradable stents are safe and effec-
tive options for the relief of pancreatic outflow obstruction, and eventually of the 
pain [89–91] Although celiac plexus (endoscopic or percutaneous) is still commonly 
used in clinical practice, the evidence for its efficacy of celiac plexus block in CP 
remains weak [92].
8.2 Treatment of the pancreatic duct stones
Pancreatic stones are the result of the CP and they are usually getting calcified 
with progression of the disease [93]. Pancreatic ductal stones which cause symp-
toms such as pain by obstructing the flow of pancreatic juice, recurrent episodes of 
pancreatitis, or present with pseudocyst or fistula and other complications can be 
treated by endoscopic methods [94].
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The location of the stone in the duct and its number is important for deciding 
endoscopic methods. Stones in the head and neck of the pancreas can be extracted 
with endoscopy, with or without stent replacement. However, endoscopic treatment 
is not suitable for stones, which already caused overt local complications or are 
located distally [85, 95, 96].
Pancreatic duct stones smaller than 5 mm are extracted by the ERCP, while 
extracorporeal shock wave lithotripsy (ESWL) is suggested for the clearance of 
radiopaque obstructive stones larger than 5 mm. Furthermore, recent studies sug-
gest that performance of ESWL prior to the endoscopic attempt at stone extraction 
can provide more successful stone clearance [97–99].
8.3 Treatment of the pancreatic pseudocyst
Pancreatic pseudocysts develop as a frequent complication between 20 and 40% 
of CP patients [100]. It is most prevalent in alcoholic CP, followed by idiopathic 
CP [101, 102]. Almost 40% of the pseudocyst, especially smaller ones can resolve 
within the 6 weeks after the attack. However, if it does not, the probability for a 
complication such as infection or rupture is 2/3 of all cases. Endoscopic drainage, 
which has a lower morbidity rate than surgery, is a successful treatment strategy 
for a symptomatic or complicated pseudocyst [103]. There are two main technics 
for the drainage of the pseudocyst: transmural or transpapillary drainage. Whereas 
transmural drainage can be applied to every pseudocyst, transpapillary drainage 
is feasible, only if the pseudocyst has a connection to major pancreatic duct [104]. 
It is recommended that EUS- guided access has higher technical success than the 
conventional approach [105]. Another important consideration when planning a 
pseudocyst drainage is the existence of pseudoaneurysms and portal hypertension. 
EUS guided drainage is recommended in case of portal hypertension as bleeding 
is common complication in these patients [106]. And since the mortality is very 
high due to ruptured aneurysms, embolization of the artery prior to the endoscopic 
intervention is recommended [107].
8.4 Treatment of the biliary strictures
Biliary strictures are big obstacles during CP treatment. They are prevalent 
almost 46% of the CP patients. The symptoms include abdominal pain, jaundice, 
fever and the laboratory results show elevated serum alkaline phosphatase and/or 
bilirubin [108]. The endoscopic therapy is found to be long term effective only in 
1/3 of the endoscopically treated patients. Therefore, endoscopic management is 
mostly used as transient therapy before the surgery [109, 110]. Studies suggest that 
placement of multiple plastic stents into the bile duct to treat bile duct obstruction 
in patients with chronic pancreatitis [111]. An important point about this clinical 
picture is absolute exclusion of the malignancy. It is essential to exchange the stents 
every 3 months to prevent the occlusion. However, this period is not such critical in 
multiple stents [111].
9. Surgical treatment
When medical treatments fail, endoscopy and surgical resection, drainage 
procedures, or both can be used to relieve pain. These procedures are used to treat 
pancreatic ductal obstruction caused by stones, strictures, or both in order to relieve 
intraductal hypertension and thereby pain [112]. Whether surgical or endoscopic 
therapy should be offered first is controversial [2].
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Despite weaknesses in the study design, two randomized controlled trials found 
that surgery offered greater long-term pain relief than endoscopy [95, 96, 113]. This 
effect may be explained by the fact that surgical treatment not only relieves ductal 
hypertension by allowing drainage, but also removes inflamed tissue that causes 
neural changes and pain [114, 115]. In another clinical trial, comparing the cost-
effectiveness of endoscopy and surgery, 38 CP patients were equally randomized 
and the mean number of ERCPs performed in the endoscopy group (6.3 vs. 0.4) was 
higher than in the surgery group [116].
Many patients prefer endoscopic therapy at first, in spite of the efficacy of 
surgery and frequent need for repeated procedures among people undergoing 
endoscopy because it is less invasive [112]. Patients with large inflammatory mass 
of the pancreatic head, distal pancreatic stenosis, and pancreatic head calcifica-
tions can be challenging to treat by endoscopy [85]. If endotherapy fails to provide 
immediate symptom relief without the need for repeated endoscopies, surgery 
should be considered by a multidisciplinary team [2]. Endoscopy is most frequently 
used as a therapeutic trial to determine patients most likely to benefit from surgery. 
While this approach is intuitive, the clinical evidence supporting this approach is 
not robust and more methods for predicting pain response are urgently required to 
prevent unhelpful interventions [117].
Surgery can be an effective first-line treatment for patients with CP who have 
large and multiple pancreatic stones or complicated strictures, an inflammatory 
mass of the head or a disease confined to the pancreatic tail [112]. Patients who 
are referred within 3–5 years of the onset of symptoms and have had less than four 
endoscopic procedures prior to surgery have better surgical outcomes [118].
The type of surgery is determined by the anatomy, the course of the disease, and 
local preferences [119]. The surgical approaches used to treat patients with CP are 
drainage options, resection options and neuroablative procedures [120]. Drainage 
options are cystojejunostomy, laterolateral pancreaticojejunostomy (Partington-
Rochelle procedure) and caudal drainage (Puestow procedure). Resection options 
are pancreaticoduodenectomy (PD/Kausch-Whipple procedure) or pylorus 
preserving pancreaticoduodenectomy (PPPD/Traverso-Longmire-procedure), 
duodenum-preserving pancreatic head resection (DPPHR (Beger, Frey, Hamburg, 
Berne)), V-shaped excision, segmental resection and distal/total pancreatectomy. 
Neuroablative procedures are percutaneous radiofrequency ablation of the splanch-
nic nerves and thoracoscopic splanchnicectomy [120].
Total pancreatectomy accompanied by digestion of the pancreas, isolation of 
the islet cells and infusion into the patient’s portal circulation is a radical surgical 
alternative that enables glucose homeostasis to be maintained without the need for 
immunosuppression of allogeneic islet transplantation [121]. Outside of the United 
States, total pancreatectomy with autoislet transplantation is still not widely available 
[2] . The primary indication for total pancreatectomy and islet auto transplantation 
is intractable pain that has a significant effect on quality of life (TPIAT) according to 
current clinical guidelines [122]. The procedure is successful in reducing or eliminat-
ing pain with a positive impact on quality of life [121–123]. However, severe pain 
persists in a large number of patients even after total pancreatectomy [124].
10. Treatment of endocrine insufficiency/CP-related DM
CP-related DM (CP-DM) is the most frequent cause of pancreatogenic DM 
(which has also been referred to as type 3c DM). Biannual fasting glucose and gly-
cated hemoglobin should be obtained to assess for diabetes in CP patients [70]. The 
management of type 3c diabetes follows general recommendations for diabetics. A 
Pancreatitis
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healthy lifestyle with regular exercise and a balanced diet should accompany medi-
cal treatment. Optimized pancreatic enzyme replacement therapy improves duo-
denal sensing and uptake of complex nutrients, thus stabilizes blood sugar levels. 
Due to a lack of counter regulation, patients with type 3c diabetes have an increased 
risk for hypoglycemia and should be counseled accordingly. The treatment of 
choice is often insulin, but in mild hyperglycemia (HbA1c <8%) metformin has also 
been recommended [2]. In addition to its glucose lowering effect, a meta-analysis 
of 12 observational studies showed that metformin reduced the risk of pancreatic 
cancer development in people with diabetes [125]. Sulfonylureas should be avoided. 
Although glinides, thiazolidinediones, α-glycosidase inhibitors, incretin-based 
therapies, and SGLT2 inhibitors have not been tested in randomized trials, they may 
be effective in certain cases [61]. In order to understand the pathogenesis better and 
to inform the prevention and treatment of CP-DM, a detailed characterization of 
changes in glucose homeostasis in CP DM compared to type 2 DM is required [61].
11. Treatment of exocrine pancreatic insufficiency
The assessment of functional deficiencies should be part of the initial evalua-
tion and monitoring of patients with CP. Exocrine pancreatic insufficiency (EPI) 
is indicated by symptoms of steatorrhea (foul-smelling, oily stool), diarrhea, and 
weight loss. The gold standard for the diagnosis of EPI is a decreased coefficient of fat 
absorption (CFA) [1]. CFA of less than 93% (or >7 g of fat per 24 hours from a 72-hour 
fecal fat collection in a patient who is consuming 100 g of dietary fat each day during 
stool collection) defines steatorrhea or fat malabsorption [112]. Although this is a 
highly accurate test for fat malabsorption, it is rarely used in clinical practice because 
it is difficult for patients to perform properly. Several other indirect measures (e.g. 
fecal elastase (FE-1), serum trypsin) and clear tests (endoscopic secretin) are used 
to diagnose exocrine insufficiency [126]. The accuracy of these tests is highest in the 
presence of severe exocrine insufficiency (defined as steatorrhea). FE −1 is an indirect 
measure of exocrine function that is performed on a random stool sample. Since 
false positive test results are common due to diarrhea, the fecal elastase-1 test should 
not be used to evaluate patients with unexplained diarrhea [127]. Furthermore, the 
sensitivity and specificity of this test is open to discuss [126]. Shortly, there are no 
established criterion standard for mild to moderate exocrine insufficiency. The lack of 
a reliable and easy test to diagnose and monitor the treatment of EPI remains one of 
the biggest challenges for the management of EPI. All patients with chronic pancre-
atitis and pancreatic exocrine insufficiency, or signs of malnutrition should be treated 
with 40,000–50,000 lipase units of pancreatic enzymes per meal, and dose should 
be increased until symptoms are relieved [2]. In patients with EPI with persistent 
symptoms despite pancreatic enzyme replacement therapy (PERT) initiation, addi-
tional treatment strategies to consider are increase in the dosage of PERT, addition of 
a proton pump inhibitor (if not currently used), consideration of alternative etiologies 
of symptoms in CP, such as small intestinal bacterial overgrowth or lactose intoler-
ance, and consideration of other causes of fat malabsorption [128]. According to a 
large randomized controlled trial in unselected noncritically ill inpatients, nutritional 
evaluation and treatment can reduce morbidity and mortality [129].
12. Treatment of metabolic bone disorder
The high prevalence of CP-related osteopathy can be partly explained by 
common risk factors such as cigarette smoking and heavy alcohol consumption. 
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Furthermore, chronic inflammation caused by CP is likely to contribute to a pro-
inflammatory environment that leads to net bone loss [130]. Ultimately, patients 
with CP are at high risk of vitamin D deficiency, especially when EPI is present [131].
CP-associated osteopathy management follows general treatment guidelines, 
including calcium and vitamin D supplementation, weight-bearing exercises, 
and smoking cessation. Oral bisphosphonate therapy, when indicated, should be 
closely monitored to ensure that patients tolerate it. If patient cannot tolerate it, 
switching to an alternative anti-resorptive therapies should be considered. Lastly, 
uncontrolled data indicates that PERT could potentially reduce the risk of fractures 
in subjects with CP, but further studies are required before this can be universally 
recommended [132].
In other gastrointestinal conditions, such as celiac disease, cholestatic liver 
disease, and inflammatory bowel disease, baseline screening with a DEXA scan has 
been widely adopted. That is why, baseline screening with DEXA in CP is reason-
able considering that CP has higher odds of fractures compared with other gastroin-
testinal conditions [67, 71].
13. CP and pancreatic cancer surveillance
Pancreatic cancer is expected to be the second to third most common cause 
of cancer-related deaths by 2030 due to late diagnosis and inadequate treatment 
choices [133]. The relationship between chronic pancreatitis and pancreatic cancer 
is complicated since common risk factors and the course of the disease affect the 
rate of malignant transformation [2]. Epidemiological studies have consistently 
demonstrated an increased risk of pancreatic cancer (i.e., pancreatic ductal 
adenocarcinoma) in patients with CP, which is thought to be a result of chronic 
inflammation leading to hyperproliferation of pancreatic stellate cells [134]. In a 
meta-analysis, the risk of developing pancreatic cancer is increased in patients with 
chronic pancreatitis, but this is potentially confounded by smoking, which is an 
independent risk factor [135, 136].
Patients with hereditary pancreatitis have a 70-fold increased risk of develop-
ing pancreatic cancer compared to the control population [137, 138]. Patients with 
tropical pancreatitis can have a relative risk of more than 100; however, recent 
updates are required to see if there has been a similar decline over time [139].
Patients with hereditary chronic pancreatitis should be screened starting at age 
40 or 20 years after the diagnosis of chronic pancreatitis, regardless of gene car-
rier status.
While PDAC screening is not routinely recommended, it is advised to retain high 
clinical suspicion in those with unexplained symptoms, such as unexplained weight 
loss or changes in abdominal pain characteristics [1, 71]. In all patients with chronic 
pancreatitis, newly diagnosed diabetes may be an early sign of pancreatic cancer 
and may prompt further research. Unfortunately, the baseline morphological 
changes in the pancreas (especially the main pancreatic duct dilatation) in CP make 
it difficult to recognize a small neoplasm in cross-sectional imaging. In patients 
with multiple calcifications which may mask changes in the parenchyma, there is a 
chance of sampling error with EUS-guided fine needle aspiration [1].
14. Conclusion
CP is a multifactorial disease resulting in fibroinflammatory changes, endocrine 
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as alcohol, hereditary changes are well established, idiopathic cases constitute a 
considerable percentage. Both the endoscopic and radiologic techniques are helping 
the clinicians for diagnosing the disease. Medical, endoscopic and surgical treat-
ment options are also effective and long-lasting. The main challenge in the field is 
early diagnosis of the CP before the symptoms exaggerate and staging the disease 
to monitor and treat the patients in a more appropriate way. Therefore, future 
prospective clinical trials and translational studies in search of novel diagnostic 
markers and staging methods are absolutely needed.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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